|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | p16INK4a Gene Promoter Hypermethylation in Mucosa as a Prognostic Factor for Patients with Colorectal Cancer显示文摘 | Wettergren Y Odin E Nilsson G | 2008 | Mol Med2008，14，78： | 1 |
| 2 | P16INK4a gene promoter hypermethylation in mucosa as a prognositie factor for patients with eolorectal cancer显示文摘 | Wettergren Y Odin E Nilsson S | 2008 | Mol Med2008，14，78： | 1 |
| 3 | Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients显示文摘 | ODIN E WETTERGREN Y NILSSON S | 2003 | Clin Cancer Res2003，9，161： | 1 |
| 4 | Conceptual and Operational Aspects of Brand Loyalty:An Empirical Investigation 显示文摘 | Odin Y Odin N Valette-Florence P | 2001 | Journal of Business Research2001，53，2： | 1 |
| 5 | Coneeptual and operational aspects of brand loyalty显示文摘 | Odin Y Odin N Valette- Florence P | 2001 | Journal of business research2001，53，8： | 1 |
| 6 | Expression and clinical signifi-cance of methylenetetrahydrofolate reductase in patients with colorectal cancer显示文摘 | Odin E Wettergren Y Carlsson G | 2006 | Clin Colorectal Cancer2006，5，5： | 1 |
| 7 | A study of the MTHFR gene polymorphism C677T in colorectal cancer显示文摘 | Derwinger K Wettergren Y Odin E | 2009 | Clin Colorectal Cancer2009，8，1： | 1 |
| 8 | MTHFR, MTR, and MTRR polymorphisms in relation to pl61NK4A hypermethylation in mucosa of patients with colorectal cancer显示文摘 | Wettergren Y Odin E Carlsson G Gustavsson B | 2010 | Mol Med2010，16，910： | 1 |
| 9 | A study of the MTHFR gene polymorphism C677T in colorectal cancer 显示文摘 | DERWINGER K WETTERGREN Y ODIN E | 2009 | Clin Colorectal Cancer2009，8，1： | 1 |
| 10 | Gene polymorphisms MTHFRC677T and MTRA2756G as predictive factors in adjuvant chemotherapy for stage III colorectal显示文摘 | Taflin H Wettergren Y Odin E Carlsson G | | 0，，09： | 1 |
| 11 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs. | Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Virology2017，6，4： | 1 |
| 12 | Altered Gene Expression of Folate Enzymes in Adjacent Mucosa Is Associated with Outcome of Colorectal Cancer Patients显示文摘 | Odin E Wettergren Y Nilsson S | 2003 | Clin Can Res2003，9，： | 1 |
| 13 | Is obesity associated with injuries among young people?显示文摘 | Bazelmans C Coppieters Y C odin I | 2004 | Eur J Epidemiol2004，19，11： | 1 |
| 14 | Ecotoxicological risk assessment linked to infilling quarries with treated dredged seaport sediments 显示文摘 | Pert'odin Y Donguy G Bazin C | 2012 | Science of the Total Environment2012，431，： | 1 |
| 15 | A phase Ⅱ trail of single-agent bevacizumab in patients with recurrent anaplastic glioma显示文摘 | KREISL T ZHANG W ODIN Y | 2011 | Neuro Oncol2011，13，10： | 1 |
| 16 | Anemia of uremia is associated with reduced in vitro cytokine secretion: immunopotentiating activity of red blood cells 显示文摘 | Gafter U Kaleehman Y Odin J B | 1998 | Kidney Int1998，45，1： | 1 |
| 17 | Conceptual and Operational Aspects of Brand Loyalty: an Empirical Investigation显示文摘 | Odin Y Odin N Valette-Florence P | 2001 | Journal of Business Research2001，53，： | 1 |
| 18 | Conceptual and Operational Aspects of Brand Loyalty :'An Empirical Investigation显示文摘 | Odin Y Odin N Florence P V | 2001 | Journal of Business Research2001，，2： | 1 |
| 19 | p16INK4a gene promoter hypermethylation in mucosa as a prognostic factor for patients with colorectal cancer 显示文摘 | Wettergren Y Odin E Gustavsson B | 2008 | Mol Med2008，14，78： | 1 |
| 20 | Conceptual and Operational Aspects of Brand Loyalty:an Empirical Investigation 显示文摘 | Odin Y Odin N and Valette-Florence P | 2001 | Journal of Business Research2001，，53： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员